More international groups conducting larger studies are expected to investigate both the frequencies of the anti‐NF186 and anti‐CNTN1 autoantibodies, clinical features, and treatment responses of CIDP patients in different populations and countries. This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.